Pranav Saha sees himself as a person with #BetaThalassemia, not a thalassemia patient. Hear this sailor, rock climber, scuba diver and overall adventure traveler share how he doesn’t let his disease define him. Learn more about our commitment to the beta thalassemia community and our hope for the future: https://lnkd.in/ezfq7XCP
关于我们
Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious and life-threatening diseases. We discovered and developed the first medicines to treat the underlying cause of cystic fibrosis (CF), a rare, life-threatening genetic disease. In addition to clinical development programs in CF, Vertex has more than a dozen ongoing research programs focused on the underlying mechanisms of other serious diseases. Founded in 1989 in Cambridge, Massachusetts, our corporate headquarters is now located in Boston’s Innovation District, and our international headquarters is in London, United Kingdom. We currently employ approximately 3,500 people in the United States, Europe, Canada, Australia and Latin America with nearly two-thirds of our staff dedicated to research and development. Vertex is consistently recognized as one of the industry’s top places to work by Science Magazine, The Boston Globe, Boston Business Journal and the San Diego Business Journal. Our research and medicines have also received esteemed recognitions, including the Robert J. Beall Therapeutics Development Award, the French Prix Galien and the British Pharmacological Society awards.
- 网站
-
https://www.vrtx.com/
Vertex Pharmaceuticals的外部链接
- 所属行业
- 生物技术研究
- 规模
- 1,001-5,000 人
- 总部
- Boston，MA
- 类型
- 上市公司
- 创立
- 1989
- 领域
- cystic fibrosis、alpha-1 antitrypsin deficiency (AATD)、APOL1-mediated kidney diseases、sickle cell disease、beta thalassemia、Duchenne muscular dystrophy和type 1 diabetes mellitus
地点
Vertex Pharmaceuticals员工
动态
-
Our unique approach to research powers our innovation at Vertex, allowing us to deliver potentially transformative solutions for patients living with serious diseases. Mark Bunnage, Head of Global Research, discusses this strategy with Pharmafocus, sharing his view on how the biotech industry is continuing to evolve, and how at Vertex we’re driven by an ambition to take on the impossible.
-
Last week we donated more than 250 computer monitors to our longstanding Vertex Foundation partner City Year UK, during a recent visit to the City of London Academy Islington. This was an exciting chance for us to see City Year mentors in action supporting students in their lessons and getting to hear from young people what motivates them to help others. It was clear to see the positive impact the mentors are having on childrens’ education, and social and emotional skills, and we saw first-hand how our monitors will aid this inspiring work at one of the many schools City Year supports across the UK. Thank you, City Year, for such an insightful day.
-
-
Our team is heading to San Diego for the American Society of Hematology Annual Meeting! We are looking forward to engaging with other professionals working in hematology as we continue to be committed to our sickle cell disease and beta thalassemia programs. #ASH2024 Learn more about our approach: https://www.vrtx.com/
-
-
In honor of Diabetes Awareness Month, we welcomed Phyllis Kaplan to the office to share her journey of living with type 1 diabetes (T1D) for 50 years. Thank you to Felicia Pagliuca, T1D Disease Area Executive, David Altshuler, Chief Scientific Officer, and of course Phyllis for an inspiring conversation that motivates us to continue our work in the hopes of transforming T1D care. To hear more from those living with T1D, visit https://lnkd.in/gceweaT8
-
-
“The word ‘serial’ is as important as ‘innovation,’” said CEO & President Reshma Kewalramani, MD FASN. We approach all our work — from blazing new paths in R&D to nurturing an inclusive culture and operating our business responsibly — as serial innovators. Because, at the end of the day, we hope our fearless pursuit of excellence will make a difference for people with serious diseases. We’re grateful to be #4 on the inaugural Forbes America’s Best Companies 2025 list, which evaluated approximately 2,000 of the largest companies in the U.S. across more than 60 measures.
-
-
A 20-year Vertexian, Tatiana Durakovic was honored with the Loyalty Award by The Admin Awards in recognition of her long-standing dedication to going above and beyond and her commitment to living our values and advancing our mission. Learn more about Tatiana’s remarkable story?? ??
Please join us in celebrating Tatiana Durakovic with Vertex Pharmaceuticals who has been presented with the Loyalty Award at the 2024 Admin Awards – Boston & New England Region. Imagine arriving in a new country, building a life from scratch, and dedicating your career to a single mission—this is the story of Tatiana Durakovic, a refugee from Serbia who found a new beginning at Vertex Pharmaceuticals. Fast forward to 20 years later, Tatiana has become an invaluable part of the fiber of Vertex, known for her diligence, diplomacy, and commitment to Vertex’s mission of transforming lives through innovative medicine. Tatiana’s dedication shines through in every aspect of her work. Supporting Vertex’s Investor Relations team, Tatiana handles everything from coordinating investor meetings to managing complex event schedules, often working after hours or weekends to ensure flawless execution. Her role requires precision, diplomacy, and adaptability, especially when coordinating with Vertex’s senior executives and high-profile investors. As one colleague shared, “Tatiana always gets it done with urgency, professionalism, and grace.” Tatiana’s journey within Vertex is a testament to her loyalty and drive. From her early roles in finance to joining the Investor Relations team, she has consistently taken on new responsibilities, embodying Vertex’s values and ensuring the success of her team. She’s the one who anticipates problems before they arise, offering solutions and removing obstacles for her team. Tatiana’s “sense of ownership and pride in her work is obvious; we have complete trust in her.” Tatiana doesn’t see her work as just a job—it’s a commitment to a cause that resonates deeply with her. A round of applause for Tatiana Durakovic, a remarkable recipient of the Loyalty Award!
-
-
A group of five individuals living with type 1 diabetes came together to share how the disease has affected their sense of independence beyond being consumed by managing their disease. Hear about the physical and emotional burdens they are forced to carry: https://lnkd.in/eWVh3W_c
-
One of the ways we continually infuse diverse perspectives into our culture is by welcoming the next generation of innovative scientists through our Vertex Fellows program. Contribute to a scientific community that understands how new therapies are made and apply to be a Vertex Fellow today: https://lnkd.in/eNsYGBQj
-
The world of drug development is complex – involving functions that range from Drug Discovery to Clinical Development to Regulatory Affairs to Commercial. That’s why we created the Vertex Physician Investigator program to help outstanding early career physician-scientists launch their careers in drug discovery and development. Hear about what this program offers and visit https://lnkd.in/g_-AUybx to apply.